
Investornewsbreaks Telomir Pharmaceuticals (NASDAQ: TELO) Reports Preclinical Success Of Telomir-1 In Prostate Cancer ...
(MENAFN- Investor Brand Network) Telomir Pharmaceuticals (NASDAQ: TELO) announced preclinical findings showing that its telomere-elongating drug, Telomir-1, reduced tumor size by approximately 50% in a prostate cancer animal model. The study demonstrated …